THYROID DYSFUNCTION AND ITS RESPONSES TO TREATMENT ARE ASSOCIATED WITH THROMBOCYTOPENIA IN CHRONIC HEPATITIS B-INFECTED SUBJECTS WITH COMPENSATORY CIRRHOSIS
(Abstract release date: 05/19/16)
EHA Library. Su Y. 06/09/16; 132967; E1418
Prof. Yan Su
Contributions
Contributions
Abstract
Abstract: E1418
Type: Eposter Presentation
Background
Many reports have demonstrated a significant relationship between thrombocytopenia and thyroid dysfunction and its treatment. However, the pathogenetic link between these conditions has not been clarified. Autoimmune theory has been well-supported hypothesis. Our previous studies have demonstrated that chronic hepatitis B (CHB) withcompensatory cirrhosis accompanied by thrombocytopenia is an important research subject. Additionally, we have observed many casesof hypothyroidism in CHBpatients with thrombocytopenia in our clinicalstudies. However, no information is available regarding the association between thyroiddysfunction and thrombocytopenia in CHBpatients with compensatory cirrhosis.
Aims
We investigated whether thrombocytopenia in patients diagnosed with CHB withcompensatory cirrhosis is related to thyroid dysfunction, and further explored the treatment and the platelet response to treatment.
Methods
Thrombocytopenia was defined as a platelet count of <100×109/L. We divided all patients into two groups based onplatelet counts of <50×109/L and >50×109/L. The prevalence of thyroid dysfunction, including normal thyroid function, overt or subclinical hyperthyroidism, and overt or subclinical hypothyroidismwas determined in each group. Thyroid function and liver function were detected periodically. During treatment, platelet counts were assessed weekly during the first month and then every 4 weeks for one year. Treatment of thyroid dysfunction and treatment responses were also recorded.
Results
A total of 261 patients were enrolled in this observational study. Among the 30(11.49%) patients with abnormal serum TSH levels, there were 6 (2.29%) with hyperthyroidism, and 24 (9.20%)with hypothyroidism, and 60% were female. Patients with a platelet count <50×109/L had a higher incidence of hypothyroidism, which developed in 11% of patients in group A (platelet count <50×109/L) compared with 8.07% in group B (platelet count >50×109/L) (P< 0.05). Serum TSH was significantly higher but serum FT3,FT4,TT3, and TT4 were significantly lower in group A (P< 0.05). We identified risk factors associated with platelet count before therapy. Logistic regression analysis showed that serum TSH, FT3, FT4,TT3 and TT4 levels were positively associated with the platelet count. We calculated the difference in platelet count from baseline for each time pointduring treatment. A greater change was exploredin group A than group B (P< 0.05). In each group, the change in platelet count was higher in patients who received treatment for their thyroid condition (P< 0.05).We further assessed factors influencing patients who had a platelet response compared with those who had no reponse. Highly significant variables associated with a platelet response, even in the multivariate analysis, included serum TSH, FT3, FT4, TT3 and TT4 levels.
Conclusion
This is the first studyto demonstratethat thyroid dysfunction, especially hypothyroidism, is common in patients with CHB accompanied by thrombocytopenia.Females are more likely to develop thyroid dysfunction. Thyroid function is associated with platelet counts. Additionally, a more dramaticplateletcountresponse was observed with administration of thyroid hormone therapy in patients with hypothyroidism, even in the multivariate analysis.It may provide a novel approach for thetreatment of thrombocytopenia in CHB patients with compensatory cirrhosis.
Session topic: E-poster
Keyword(s): Cirrhosis, Thrombocytopenia
Type: Eposter Presentation
Background
Many reports have demonstrated a significant relationship between thrombocytopenia and thyroid dysfunction and its treatment. However, the pathogenetic link between these conditions has not been clarified. Autoimmune theory has been well-supported hypothesis. Our previous studies have demonstrated that chronic hepatitis B (CHB) withcompensatory cirrhosis accompanied by thrombocytopenia is an important research subject. Additionally, we have observed many casesof hypothyroidism in CHBpatients with thrombocytopenia in our clinicalstudies. However, no information is available regarding the association between thyroiddysfunction and thrombocytopenia in CHBpatients with compensatory cirrhosis.
Aims
We investigated whether thrombocytopenia in patients diagnosed with CHB withcompensatory cirrhosis is related to thyroid dysfunction, and further explored the treatment and the platelet response to treatment.
Methods
Thrombocytopenia was defined as a platelet count of <100×109/L. We divided all patients into two groups based onplatelet counts of <50×109/L and >50×109/L. The prevalence of thyroid dysfunction, including normal thyroid function, overt or subclinical hyperthyroidism, and overt or subclinical hypothyroidismwas determined in each group. Thyroid function and liver function were detected periodically. During treatment, platelet counts were assessed weekly during the first month and then every 4 weeks for one year. Treatment of thyroid dysfunction and treatment responses were also recorded.
Results
A total of 261 patients were enrolled in this observational study. Among the 30(11.49%) patients with abnormal serum TSH levels, there were 6 (2.29%) with hyperthyroidism, and 24 (9.20%)with hypothyroidism, and 60% were female. Patients with a platelet count <50×109/L had a higher incidence of hypothyroidism, which developed in 11% of patients in group A (platelet count <50×109/L) compared with 8.07% in group B (platelet count >50×109/L) (P< 0.05). Serum TSH was significantly higher but serum FT3,FT4,TT3, and TT4 were significantly lower in group A (P< 0.05). We identified risk factors associated with platelet count before therapy. Logistic regression analysis showed that serum TSH, FT3, FT4,TT3 and TT4 levels were positively associated with the platelet count. We calculated the difference in platelet count from baseline for each time pointduring treatment. A greater change was exploredin group A than group B (P< 0.05). In each group, the change in platelet count was higher in patients who received treatment for their thyroid condition (P< 0.05).We further assessed factors influencing patients who had a platelet response compared with those who had no reponse. Highly significant variables associated with a platelet response, even in the multivariate analysis, included serum TSH, FT3, FT4, TT3 and TT4 levels.
Conclusion
This is the first studyto demonstratethat thyroid dysfunction, especially hypothyroidism, is common in patients with CHB accompanied by thrombocytopenia.Females are more likely to develop thyroid dysfunction. Thyroid function is associated with platelet counts. Additionally, a more dramaticplateletcountresponse was observed with administration of thyroid hormone therapy in patients with hypothyroidism, even in the multivariate analysis.It may provide a novel approach for thetreatment of thrombocytopenia in CHB patients with compensatory cirrhosis.
Session topic: E-poster
Keyword(s): Cirrhosis, Thrombocytopenia
Abstract: E1418
Type: Eposter Presentation
Background
Many reports have demonstrated a significant relationship between thrombocytopenia and thyroid dysfunction and its treatment. However, the pathogenetic link between these conditions has not been clarified. Autoimmune theory has been well-supported hypothesis. Our previous studies have demonstrated that chronic hepatitis B (CHB) withcompensatory cirrhosis accompanied by thrombocytopenia is an important research subject. Additionally, we have observed many casesof hypothyroidism in CHBpatients with thrombocytopenia in our clinicalstudies. However, no information is available regarding the association between thyroiddysfunction and thrombocytopenia in CHBpatients with compensatory cirrhosis.
Aims
We investigated whether thrombocytopenia in patients diagnosed with CHB withcompensatory cirrhosis is related to thyroid dysfunction, and further explored the treatment and the platelet response to treatment.
Methods
Thrombocytopenia was defined as a platelet count of <100×109/L. We divided all patients into two groups based onplatelet counts of <50×109/L and >50×109/L. The prevalence of thyroid dysfunction, including normal thyroid function, overt or subclinical hyperthyroidism, and overt or subclinical hypothyroidismwas determined in each group. Thyroid function and liver function were detected periodically. During treatment, platelet counts were assessed weekly during the first month and then every 4 weeks for one year. Treatment of thyroid dysfunction and treatment responses were also recorded.
Results
A total of 261 patients were enrolled in this observational study. Among the 30(11.49%) patients with abnormal serum TSH levels, there were 6 (2.29%) with hyperthyroidism, and 24 (9.20%)with hypothyroidism, and 60% were female. Patients with a platelet count <50×109/L had a higher incidence of hypothyroidism, which developed in 11% of patients in group A (platelet count <50×109/L) compared with 8.07% in group B (platelet count >50×109/L) (P< 0.05). Serum TSH was significantly higher but serum FT3,FT4,TT3, and TT4 were significantly lower in group A (P< 0.05). We identified risk factors associated with platelet count before therapy. Logistic regression analysis showed that serum TSH, FT3, FT4,TT3 and TT4 levels were positively associated with the platelet count. We calculated the difference in platelet count from baseline for each time pointduring treatment. A greater change was exploredin group A than group B (P< 0.05). In each group, the change in platelet count was higher in patients who received treatment for their thyroid condition (P< 0.05).We further assessed factors influencing patients who had a platelet response compared with those who had no reponse. Highly significant variables associated with a platelet response, even in the multivariate analysis, included serum TSH, FT3, FT4, TT3 and TT4 levels.
Conclusion
This is the first studyto demonstratethat thyroid dysfunction, especially hypothyroidism, is common in patients with CHB accompanied by thrombocytopenia.Females are more likely to develop thyroid dysfunction. Thyroid function is associated with platelet counts. Additionally, a more dramaticplateletcountresponse was observed with administration of thyroid hormone therapy in patients with hypothyroidism, even in the multivariate analysis.It may provide a novel approach for thetreatment of thrombocytopenia in CHB patients with compensatory cirrhosis.
Session topic: E-poster
Keyword(s): Cirrhosis, Thrombocytopenia
Type: Eposter Presentation
Background
Many reports have demonstrated a significant relationship between thrombocytopenia and thyroid dysfunction and its treatment. However, the pathogenetic link between these conditions has not been clarified. Autoimmune theory has been well-supported hypothesis. Our previous studies have demonstrated that chronic hepatitis B (CHB) withcompensatory cirrhosis accompanied by thrombocytopenia is an important research subject. Additionally, we have observed many casesof hypothyroidism in CHBpatients with thrombocytopenia in our clinicalstudies. However, no information is available regarding the association between thyroiddysfunction and thrombocytopenia in CHBpatients with compensatory cirrhosis.
Aims
We investigated whether thrombocytopenia in patients diagnosed with CHB withcompensatory cirrhosis is related to thyroid dysfunction, and further explored the treatment and the platelet response to treatment.
Methods
Thrombocytopenia was defined as a platelet count of <100×109/L. We divided all patients into two groups based onplatelet counts of <50×109/L and >50×109/L. The prevalence of thyroid dysfunction, including normal thyroid function, overt or subclinical hyperthyroidism, and overt or subclinical hypothyroidismwas determined in each group. Thyroid function and liver function were detected periodically. During treatment, platelet counts were assessed weekly during the first month and then every 4 weeks for one year. Treatment of thyroid dysfunction and treatment responses were also recorded.
Results
A total of 261 patients were enrolled in this observational study. Among the 30(11.49%) patients with abnormal serum TSH levels, there were 6 (2.29%) with hyperthyroidism, and 24 (9.20%)with hypothyroidism, and 60% were female. Patients with a platelet count <50×109/L had a higher incidence of hypothyroidism, which developed in 11% of patients in group A (platelet count <50×109/L) compared with 8.07% in group B (platelet count >50×109/L) (P< 0.05). Serum TSH was significantly higher but serum FT3,FT4,TT3, and TT4 were significantly lower in group A (P< 0.05). We identified risk factors associated with platelet count before therapy. Logistic regression analysis showed that serum TSH, FT3, FT4,TT3 and TT4 levels were positively associated with the platelet count. We calculated the difference in platelet count from baseline for each time pointduring treatment. A greater change was exploredin group A than group B (P< 0.05). In each group, the change in platelet count was higher in patients who received treatment for their thyroid condition (P< 0.05).We further assessed factors influencing patients who had a platelet response compared with those who had no reponse. Highly significant variables associated with a platelet response, even in the multivariate analysis, included serum TSH, FT3, FT4, TT3 and TT4 levels.
Conclusion
This is the first studyto demonstratethat thyroid dysfunction, especially hypothyroidism, is common in patients with CHB accompanied by thrombocytopenia.Females are more likely to develop thyroid dysfunction. Thyroid function is associated with platelet counts. Additionally, a more dramaticplateletcountresponse was observed with administration of thyroid hormone therapy in patients with hypothyroidism, even in the multivariate analysis.It may provide a novel approach for thetreatment of thrombocytopenia in CHB patients with compensatory cirrhosis.
Session topic: E-poster
Keyword(s): Cirrhosis, Thrombocytopenia
{{ help_message }}
{{filter}}